127 related articles for article (PubMed ID: 7647577)
1. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance.
Müller CG; Bayley TA; Harrison JE; Tsang R
Thyroid; 1995 Apr; 5(2):81-7. PubMed ID: 7647577
[TBL] [Abstract][Full Text] [Related]
2. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
3. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
6. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
7. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
8. Effect of replacement doses of thyroxine on bone mineral density.
Hanna FW; Pettit RJ; Ammari F; Evans WD; Sandeman D; Lazarus JH
Clin Endocrinol (Oxf); 1998 Feb; 48(2):229-34. PubMed ID: 9579237
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.
Nuzzo V; Lupoli G; Esposito Del Puente A; Rampone E; Carpinelli A; Del Puente AE; Oriente P
Gynecol Endocrinol; 1998 Oct; 12(5):333-7. PubMed ID: 9859026
[TBL] [Abstract][Full Text] [Related]
10. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Kung AW; Lorentz T; Tam SC
Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
[TBL] [Abstract][Full Text] [Related]
11. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
12. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease.
Jódar E; Martínez-Díaz-Guerra G; Azriel S; Hawkins F
Calcif Tissue Int; 2001 Aug; 69(2):84-7. PubMed ID: 11683428
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.
Franklyn J; Betteridge J; Holder R; Daykin J; Lilley J; Sheppard M
Clin Endocrinol (Oxf); 1994 Oct; 41(4):425-32. PubMed ID: 7955453
[TBL] [Abstract][Full Text] [Related]
15. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
18. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
[TBL] [Abstract][Full Text] [Related]
19. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy.
Garton M; Reid I; Loveridge N; Robins S; Murchison L; Beckett G; Reid D
Clin Endocrinol (Oxf); 1994 Dec; 41(6):747-55. PubMed ID: 7889610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]